81-LB: Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Placebo (SURPASS-1)

Abstract

Tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist (RA) for type 2 diabetes (T2D), has shown clinically meaningful glycemic control improvements and bodyweight (BW) loss in patients with T2D inadequately controlled with diet and exercise alone. We evaluated the effect of TZP treatment vs. placebo (PBO) in patient-reported outcomes (PROs) measuring health status, self-perceptions impacted by BW, and ability to perform activities of daily living. Patients were randomized (1:1:1:1) to once weekly TZP 5, 10, 15 mg, and PBO. PRO measures assessed at baseline and week 40 were: EQ-5D-5L, Impact of Weight on Self-Perceptions Questionnaire (IW-SP), and Ability to Perform Physical Activities of Daily Living (APPADL). Higher PRO scores indicate better outcomes. Scores for all PRO measures improved significantly from baseline at 40 week for all TZP doses (p Disclosure K. Boye: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Eli Lilly and Company. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. C. Lee: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. H. Mao: Employee; Self; Eli Lilly and Company. X. Cui: Employee; Self; Eli Lilly and Company. L. Fernandez lando: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. V. Thieu: None. Funding Eli Lilly and Company